Asset Details
Do you wish to reserve the book?
Cost‐effectiveness of pancreas surveillance: The CDKN2A‐p16‐Leiden cohort
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost‐effectiveness of pancreas surveillance: The CDKN2A‐p16‐Leiden cohort
Do you wish to request the book?
Cost‐effectiveness of pancreas surveillance: The CDKN2A‐p16‐Leiden cohort
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost‐effectiveness of pancreas surveillance: The CDKN2A‐p16‐Leiden cohort
2023
Overview
Background CDKN2A‐p16‐Leiden mutation carriers have a high lifetime risk of developing pancreatic ductal adenocarcinoma (PDAC), with very poor survival. Surveillance may improve prognosis. Objective To assess the cost‐effectiveness of surveillance, as compared to no surveillance. Methods In 2000, a surveillance program was initiated at Leiden University Medical Center with annual MRI and optional endoscopic ultrasound. Data were collected on the resection rate of screen‐detected tumors and on survival. The Kaplan–Meier method and a parametric cure model were used to analyze and compare survival. Based on the surveillance and survival data from the screening program, a state‐transition model was constructed to estimate lifelong outcomes. Results A total of 347 mutation carriers participated in the surveillance program. PDAC was detected in 31 patients (8.9%) and the tumor could be resected in 22 patients (71.0%). Long‐term cure among patients with resected PDAC was estimated at 47.1% (p < 0.001). The surveillance program was estimated to reduce mortality from PDAC by 12.1% and increase average life expectancy by 2.10 years. Lifelong costs increased by €13,900 per patient, with a cost‐utility ratio of €14,000 per quality‐adjusted life year gained. For annual surveillance to have an acceptable cost‐effectiveness in other settings, lifetime PDAC risk needs to be 10% or higher. Conclusion The tumor could be resected in most patients with a screen‐detected PDAC. These patients had considerably better survival and as a result annual surveillance was found to be cost‐effective.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Carcinoma, Pancreatic Ductal - diagnosis
/ Carcinoma, Pancreatic Ductal - genetics
/ Carcinoma, Pancreatic Ductal - surgery
/ CDKN2A‐p16‐Leiden mutation carriers
/ Cyclin-Dependent Kinase Inhibitor p16 - genetics
/ Females
/ Humans
/ Mutation
/ Original
/ Pancreas
/ Pancreatic Neoplasms - diagnosis
/ Pancreatic Neoplasms - epidemiology
/ Pancreatic Neoplasms - genetics
/ PDAC
/ Surgery
/ survival
